Discover how pharmaceutical innovation led by companies like Pfizer is transforming cancer treatment and shaping future breakthroughs.

ONCOLOGY:  THE ROLE OF PHARMA IN CANCER CURE

PFIZER’S ONCOLOGY IMPACT

Pfizer continues expanding its global oncology presence, driving innovation and building therapies that address the complex needs of cancer patients worldwide.

INVESTING IN CANCER RESEARCH

With 40% of its R&D budget dedicated to oncology, Pfizer is accelerating targeted therapies and combination treatments designed for diverse cancer types.

50+ PROGRAMS IN DEVELOPMENT

Pfizer’s robust pipeline includes over 50 active cancer programs, featuring small molecules, ADCs, bispecific antibodies, and next-generation immunotherapies.

2025 ASCO BREAKTHROUGHS

Key highlights include improved survival with BRAFTOVI in colorectal cancer and strong tumor-shrinkage data for SSGJ-707 in lung cancer patients.

BRAFTOVI FDA APPROVAL

The FDA’s approval of BRAFTOVI marks a major step forward for patients with BRAF V600E-mutant metastatic colorectal cancer, offering a more effective targeted option.

NEXT-GEN CANCER THERAPIES

Pfizer is advancing precision-focused treatments including small molecules, ADCs, and bispecific antibodies that directly target cancer mechanisms.

PFIZER’S 2030 VISION

By 2030, Pfizer aims to double the number of patients reached with its oncology medicines through strategic research, partnerships, and improved global availability.

MOVING TOWARD A CURE

Cancer’s complexity requires collaboration. Pfizer works with leading cancer centers to develop more precise, accessible, and patient-centered therapies for the future.

Stories

More

KIDNEY STONES AND DIARRHEA RELATIONSHIP

URINARY TRACT INFECTION AND SEXUAL RELATIONSHIP